TY - JOUR T1 - What is important for people with NTM? An EMBARC-ELF patient survey JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00807-2020 SP - 00807-2020 AU - Michal Shteinberg AU - Jeanette Boyd AU - Stefano Aliberti AU - Eva Polverino AU - Bridget Harris AU - Tove Berg AU - Annette Posthumus AU - Thomas Ruddy AU - Pieter Goeminne AU - Ernie Lloyd AU - Timothy Alan AU - Josje Altenburg AU - Barbara Crossley AU - Francesco Blasi AU - James Chalmers Y1 - 2020/01/01 UR - http://openres.ersjournals.com/content/early/2020/11/26/23120541.00807-2020.abstract N2 - The prevalence of non-tuberculous mycobacteria (NTM) pulmonary disease (NTM-pd) is rising worldwide, creating a significant health issue and an unmet need. The diagnosis and decision to treat NTM-pd are often a challenge, with complex criteria for diagnosis and multiple factors weighing in the decision to treat [1]. The treatment is lengthy, and the drugs used often associated with adverse effects. Adherence to NTM-pd management guidelines were found to be suboptimal, impacting treatment success [2], with substantial differences in physicians’ decision to treat and in their adherence to treatment guidelines [2–4].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Bohringer- Ingelheim, personal fees from Astra Zeneca, personal fees from Kamada, personal fees from Vertex pharmaceuticals, personal fees from Teva, non-financial support from Actelion, grants, personal fees and non-financial support from GSK, grants from Novartis, non-financial support from Rafa, grants from Trudell pharma, outside the submitted work.Conflict of interest: Jeanette Boyd reports and Employee of the European Lung Foundation.Conflict of interest: S. Aliberti reports advisory fees and research support from Bayer Healthcare; speaker fees from Grifols; advisory fees from Astra Zeneca ; advisory and speaker fees from Zambon; advisory and speaker fees, and research support from Chiesi and Insmed; advisory and speaker fees from GlaxoSmithKline; speaker fees from Menarini; advisory fees from ZetaCube Srl; and research support from Fisher & Paykel, all outside the submitted work.Dr. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work;. Dr. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work;. Dr. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work;. Dr. Aliberti reports personal fees from Bayer Healthcare, personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Zambon, grants and personal fees from Chiesi, grants and personal fees from INSMED, personal fees from GlaxoSmithKline, personal fees from Menarini, personal fees from ZetaCube Srl, grants from Fisher & Paykel, outside the submitted work;.Conflict of interest:Conflict of interest: Dr. Harris has nothing to disclose.Conflict of interest: Tove Berg has nothing to disclose.Conflict of interest: Annette Posthumus has nothing to disclose.Conflict of interest: Mr. Ruddy has nothing to disclose.Conflict of interest: Dr. Goeminne has nothing to disclose.Conflict of interest:Conflict of interest: Alan Timothy has nothing to disclose.Conflict of interest: Dr. Altenburg has nothing to disclose.Conflict of interest: Mrs. Crossley has nothing to disclose.Conflict of interest: F. Blasi reports a research grant and an advisory fee from AstraZeneca; a research grant from Bayer; research grants and advisory fees from Chiesi and GSK; advisory fees from Grifols, Guidotti and Insmed; a research grant and an advisory fee from Menarini; an advisory fee from Novartis; a research grant and an advisory fee from Pfizer; and advisory fees from Zambon and Vertex, all outside the submitted work.Conflict of interest: Dr. Chalmers reports grants and personal fees from Astrazeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from Glaxosmithkline, grants from Gilead Sciences, grants and personal fees from Insmed, personal fees from Novartis, personal fees from Zambon, outside the submitted work;. ER -